Molotinib/mometinib side effects and solutions

Momelotinib is a triple-target tyrosine kinase inhibitor of JAK1, JAK2 and ACVR1. It is mainly used to treat adult patients with moderate to high-risk myelofibrosis (MF) and anemia. As a new targeted drug approved by the FDA in recent years, molotinib has shown unique efficacy in relieving splenomegaly, controlling symptoms, and improving anemia. It is especially superior to traditional ruxolitinib in anemia. However, its use is also accompanied by certain side effects, which requires close clinical monitoring and intervention.

Clinical studies such asSIMPLIFY-1 and SIMPLIFY-2 have shown that the most common adverse reactions of molotinib include thrombocytopenia, diarrhea, dizziness, fatigue, nausea and upper respiratory tract infection. Approximately more than 20% of patients will experience varying degrees of thrombocytopenia. Therefore, baseline platelet levels should be assessed before treatment and regularly monitored during treatment. If severe thrombocytopenia occurs, dose reduction or temporary discontinuation of the drug may be considered. Diarrhea and nausea are usually mild to moderate and can be managed symptomatically with the combined use of antidiarrheal or antinausea drugs, and dietary modification can also have an auxiliary effect.

Nervous system adverse reactions such as peripheral neuropathy are one of the more concerning side effects. Some patients report numbness, tingling or abnormal sensation in their hands and feet, which may be related to the effect of the drug on the nerve conduction mechanism. Once neurological symptoms occur, neuroelectrophysiological evaluation should be performed promptly, and the dose should be adjusted or the treatment plan changed according to the severity. Regarding the risk of infection, especially fungal infection, patients with suppressed immune function need to be particularly vigilant, and some high-risk patients may require preventive anti-infective treatment.

During the post-marketing surveillance of molotinib, there have been reports indicating that rare but noteworthy adverse reactions such as blurred vision, flushing, and hypotension may occur. Doctors should regularly review blood counts, liver and kidney functions, neurological signs, and infection indicators when using this drug to maximize safety.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib